Phase IB Trial of Induction Nivolumab or Nivolumab/Ipilimumab Prior to Concurrent Chemoradiation Plus Nivolumab in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- 26 Jul 2018 Ipilimumab has been replace with Relatlimab
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 12 Jun 2017 Status changed from not yet recruiting to recruiting.